Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Walter M. Stadler

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Stadler, Walter M.

Item TypeName
Concept Vascular Endothelial Growth Factor Receptor-2
Concept Vascular Endothelial Growth Factor Receptor-3
Concept Receptors, Vascular Endothelial Growth Factor
Concept Vascular Endothelial Growth Factor Receptor-1
Academic Article A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Academic Article Targeted agents for the treatment of advanced renal cell carcinoma.
Academic Article Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Academic Article Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Academic Article Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
Academic Article Sorafenib.
Academic Article New targets, therapies, and toxicities: lessons to be learned.
Academic Article Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
Academic Article Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Academic Article Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.
Academic Article Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Academic Article Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Academic Article Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Academic Article A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

Search Criteria
  • Receptors Vascular Endothelial Growth Factor